%PDF-1.6
%
1 0 obj
<>
endobj
2 0 obj
<>stream
Henk-Jan van den Ham, Jason D. Cooper, Jakub Tomasik, Sabine Bahn, Joeri L. Aerts, Albert D. M. E. Osterhaus, Rob A. Gruters, Arno C. Andeweg, on behalf of the DC-TRN trial investigators
Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment
www.plosone.org
www.plosone.org
endstream
endobj
3 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 12 0 R/Annots 13 0 R/Contents 14 0 R/TrimBox[0 0 612 792]>>
endobj
13 0 obj
[15 0 R 16 0 R 17 0 R 18 0 R 19 0 R 20 0 R 21 0 R 22 0 R 23 0 R 24 0 R 25 0 R 26 0 R 27 0 R 28 0 R 29 0 R 30 0 R 31 0 R]
endobj
15 0 obj
<>/Border[0 0 0]/Dest(Rpone.0192278.ref001)>>
endobj
16 0 obj
<>/Border[0 0 0]/Dest(Rpone.0192278.ref002)>>
endobj
17 0 obj
<>/Border[0 0 0]/Dest(Rpone.0192278.ref003)>>
endobj
18 0 obj
<>/Border[0 0 0]/Dest(Rpone.0192278.ref005)>>
endobj
19 0 obj
<>/Border[0 0 0]/Dest(Rpone.0192278.ref002)>>
endobj
20 0 obj
<>/Border[0 0 0]/Dest(Rpone.0192278.ref006)>>
endobj
21 0 obj
<>/Border[0 0 0]/Dest(Rpone.0192278.ref007)>>
endobj
22 0 obj
<>/Border[0 0 0]/Dest(Rpone.0192278.ref008)>>
endobj
23 0 obj
<>/Border[0 0 0]/Dest(Rpone.0192278.ref009)>>
endobj
24 0 obj
<>/Border[0 0 0]/Dest(Rpone.0192278.ref008)>>
endobj
25 0 obj
<>/Border[0 0 0]/Dest(Rpone.0192278.ref010)>>
endobj
26 0 obj
<>/Border[0 0 0]/Dest(Rpone.0192278.ref010)>>
endobj
27 0 obj
<>/Border[0 0 0]/Dest(Rpone.0192278.g001)>>
endobj
28 0 obj
<>/Border[0 0 0]/Dest(Rpone.0192278.t001)>>
endobj
29 0 obj
<>/Border[0 0 0]/Dest(Rpone.0192278.ref011)>>
endobj
30 0 obj
<>/Border[0 0 0]/Dest(Rpone.0192278.ref010)>>
endobj
31 0 obj
<>/Border[0 0 0]/A 32 0 R>>
endobj
32 0 obj
<>
endobj
14 0 obj
[33 0 R 34 0 R 35 0 R 36 0 R 37 0 R 38 0 R 39 0 R 40 0 R 41 0 R 42 0 R 43 0 R 44 0 R 45 0 R 46 0 R]
endobj
33 0 obj
<>stream
q
0.45 0.36 0.35 0.01 k
0 w
575.9997 547.1144 m
199.9998 547.1144 l
199.9998 547.6144 l
575.9997 547.6144 l
f*
0.83 0.64 0.02 0 k
298.4882 432.9071 m
303.2504 432.9071 l
h
f*
305.5181 432.9071 m
310.2803 432.9071 l
h
f*
355.6913 419.9244 m
360.4535 419.9244 l
h
f*
365.6693 419.9244 m
370.3748 419.9244 l
h
f*
275.9244 393.9024 m
280.6866 393.9024 l
h
f*
350.2488 367.937 m
355.011 367.937 l
h
f*
303.4772 315.9496 m
308.2394 315.9496 l
h
f*
310.5071 315.9496 m
315.2693 315.9496 l
h
f*
405.8079 302.9102 m
410.5701 302.9102 l
h
f*
373.663 250.9228 m
378.4252 250.9228 l
h
f*
450.1417 224.9008 m
459.6661 224.9008 l
h
f*
439.7669 185.8961 m
449.2913 185.8961 l
h
f*
362.211 159.9307 m
381.7701 159.9307 l
h
f*
532.0063 159.9307 m
561.1465 159.9307 l
h
f*
381.7134 133.9087 m
391.2378 133.9087 l
h
f*
203.4142 94.9039 m
212.9386 94.9039 l
h
f*
0 g
1 j
1 J
9.5 0 0 9.5 200.0125 707.7543 cm
BT
/F0 1 Tf
1 TL
-0.0042 Tc
0 0 Td
(reactivation)Tj
5.2694 0 Td
(following)Tj
4.052 0 Td
(cART)Tj
2.7093 0 Td
(interruption)Tj
5.1561 0 Td
(also)Tj
2.029 0 Td
(affects)Tj
3.139 0 Td
(multiple)Tj
3.6224 0 Td
(analytes,)Tj
4.1773 0 Td
(but)Tj
1.5934 0 Td
(cART)Tj
2.7093 0 Td
(interruption)Tj
-34.4572 -1.474 Td
(itself)Tj
2.2498 0 Td
(only)Tj
2.029 0 Td
(has)Tj
1.8141 0 Td
(only)Tj
2.029 0 Td
(a)Tj
0.7699 0 Td
(minor)Tj
2.6914 0 Td
(effect.)Tj
2.9241 0 Td
(We)Tj
1.7127 0 Td
(find)Tj
1.8082 0 Td
(that)Tj
1.8739 0 Td
(Thyroxine-Binding)Tj
8.1816 0 Td
(Globulin)Tj
3.8372 0 Td
(\(TBG\))Tj
2.9302 0 Td
(levels)Tj
-34.8511 -1.474 Td
(and)Tj
1.8619 0 Td
(late-stage)Tj
4.5652 0 Td
(neutrophil)Tj
4.5474 0 Td
(numbers)Tj
4.0699 0 Td
(correlate)Tj
4.064 0 Td
(with)Tj
1.9753 0 Td
(the)Tj
1.5933 0 Td
(time)Tj
2.0947 0 Td
(off)Tj
1.3248 0 Td
(cART)Tj
2.7034 0 Td
(after)Tj
2.202 0 Td
(DC)Tj
1.6531 0 Td
(vaccination.)Tj
-32.655 -1.474 Td
(Furthermore,)Tj
5.9497 0 Td
(analysis)Tj
3.7835 0 Td
(shows)Tj
3.0256 0 Td
(that)Tj
1.8738 0 Td
(cART)Tj
2.7034 0 Td
(alters)Tj
2.6377 0 Td
(several)Tj
3.4075 0 Td
(regulators)Tj
4.6071 0 Td
(of)Tj
1.0503 0 Td
(blood)Tj
2.6257 0 Td
(glucose)Tj
3.6224 0 Td
(levels,)Tj
-35.2867 -1.474 Td
(including)Tj
4.1057 0 Td
(C-peptide,)Tj
4.7741 0 Td
(chromogranin)Tj
6.0453 0 Td
(-A)Tj
1.2114 0 Td
(and)Tj
1.8679 0 Td
(leptin.)Tj
2.8525 0 Td
(HIV)Tj
1.8738 0 Td
(reactivation)Tj
5.2695 0 Td
(is)Tj
0.9309 0 Td
(associated)Tj
4.9472 0 Td
(with)Tj
1.9753 0 Td
(the)Tj
-35.8536 -1.474 Td
(upregulation)Tj
5.6454 0 Td
(of)Tj
1.0443 0 Td
(CXCR3)Tj
3.5806 0 Td
(ligands.)Tj
ET
Q
q
1 j
1 J
0 w
11.4998 0 0 11.4998 200.0125 605.5937 cm
BT
/F2 1 Tf
1 TL
-0.0035 Tc
0 0 Td
(Conclusions)Tj
ET
Q
q
1 j
1 J
0 w
9.5 0 0 9.5 200.0125 588.6425 cm
BT
/F0 1 Tf
1 TL
-0.0042 Tc
0 0 Td
(Chronic)Tj
3.6223 0 Td
(HIV)Tj
1.8739 0 Td
(infection)Tj
3.8968 0 Td
(leads)Tj
2.5781 0 Td
(to)Tj
1.0443 0 Td
(a)Tj
0.7698 0 Td
(change)Tj
3.4613 0 Td
(in)Tj
0.9846 0 Td
(multiple)Tj
3.6164 0 Td
(plasma)Tj
3.4076 0 Td
(analyte)Tj
3.4075 0 Td
(levels,)Tj
3.0137 0 Td
(as)Tj
1.2651 0 Td
(does)Tj
2.3632 0 Td
(virus)Tj
-35.3046 -1.474 Td
(reactivation)Tj
5.2694 0 Td
(after)Tj
2.2021 0 Td
(cART)Tj
2.7093 0 Td
(interruption.)Tj
5.4305 0 Td
(Furthermore,)Tj
5.9498 0 Td
(we)Tj
1.4859 0 Td
(find)Tj
1.8082 0 Td
(evidence)Tj
4.1714 0 Td
(for)Tj
1.3786 0 Td
(the)Tj
1.5933 0 Td
(involvement)Tj
5.4962 0 Td
(of)Tj
-37.4947 -1.474 Td
(TBG)Tj
2.2736 0 Td
(and)Tj
1.8619 0 Td
(neutrophils)Tj
5.0487 0 Td
(in)Tj
0.9846 0 Td
(the)Tj
1.5934 0 Td
(response)Tj
4.2848 0 Td
(to)Tj
1.0503 0 Td
(DC-vaccination)Tj
6.9165 0 Td
(in)Tj
0.9847 0 Td
(the)Tj
1.5933 0 Td
(setting)Tj
3.133 0 Td
(of)Tj
1.0503 0 Td
(HIV-infection.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 489.9968 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Introduction)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 472.9889 cm
BT
/F5 1 Tf
1 TL
-0.004 Tc
0 0 Td
(Chronic)Tj
3.5262 0 Td
(HIV)Tj
2.024 0 Td
(infection)Tj
3.7927 0 Td
(is)Tj
0.8447 0 Td
(characterized)Tj
5.5615 0 Td
(by)Tj
1.1792 0 Td
(profound)Tj
4.0139 0 Td
(changes)Tj
3.4072 0 Td
(in)Tj
1.0318 0 Td
(immune)Tj
3.6283 0 Td
(function)Tj
3.6284 0 Td
(that,)Tj
2.0012 0 Td
(if)Tj
0.7767 0 Td
(left)Tj
-35.4158 -1.2982 Td
(untreated,)Tj
4.2972 0 Td
(will)Tj
1.6611 0 Td
(result)Tj
2.4492 0 Td
(in)Tj
1.0374 0 Td
(AIDS.)Tj
2.6816 0 Td
(A)Tj
0.9014 0 Td
(gradual)Tj
3.2258 0 Td
(decline)Tj
3.0841 0 Td
(of)Tj
1.0148 0 Td
(CD4)Tj
2.0919 0 Td
(T)Tj
0.8334 0 Td
(cells)Tj
1.9219 0 Td
(is)Tj
0.8447 0 Td
(a)Tj
0.6576 0 Td
(hallmark)Tj
3.7928 0 Td
(of)Tj
1.0148 0 Td
(untreated)Tj
4.0762 0 Td
(HIV)Tj
-35.5859 -1.2983 Td
(infection,)Tj
4.0138 0 Td
(but)Tj
1.5534 0 Td
(other)Tj
2.347 0 Td
(immune)Tj
3.6284 0 Td
(cells)Tj
1.9218 0 Td
(including)Tj
4.0422 0 Td
(CD8)Tj
2.092 0 Td
(T)Tj
0.8333 0 Td
(cells)Tj
1.9219 0 Td
(and)Tj
1.7291 0 Td
(B)Tj
0.7994 0 Td
(cells)Tj
1.9219 0 Td
(also)Tj
1.7688 0 Td
(have)Tj
2.0579 0 Td
(altered)Tj
2.9424 0 Td
(numbers)Tj
-33.5733 -1.3039 Td
(and)Tj
1.7291 0 Td
(turnover)Tj
3.7247 0 Td
(dynamics)Tj
4.0535 0 Td
([)Tj
0.83 0.64 0.02 0 k
(1)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
(2)Tj
0 g
(].)Tj
2.3017 0 Td
(At)Tj
1.2019 0 Td
(the)Tj
1.474 0 Td
(functional)Tj
4.3086 0 Td
(level,)Tj
2.2394 0 Td
(a)Tj
0.652 0 Td
(pathognomonic)Tj
6.5876 0 Td
(feature)Tj
2.9877 0 Td
(of)Tj
1.0148 0 Td
(HIV)Tj
2.0239 0 Td
(infec-)Tj
-34.2989 -1.2983 Td
(tion)Tj
1.8425 0 Td
(is)Tj
0.8447 0 Td
(generalized)Tj
4.7622 0 Td
(immune)Tj
3.6283 0 Td
(activation)Tj
4.1499 0 Td
([)Tj
0.83 0.64 0.02 0 k
(3)Tj
0 g
()Tj
0.83 0.64 0.02 0 k
(5)Tj
0 g
(].)Tj
2.5965 0 Td
(While)Tj
2.6532 0 Td
(combined)Tj
4.2406 0 Td
(antiretroviral)Tj
5.5105 0 Td
(treatment)Tj
4.1386 0 Td
(\(cART\))Tj
-34.367 -1.2982 Td
(curbs)Tj
2.4094 0 Td
(viral)Tj
1.9956 0 Td
(replication)Tj
4.524 0 Td
(and)Tj
1.7292 0 Td
(thereby)Tj
3.2258 0 Td
(reverses)Tj
3.4072 0 Td
(CD4)Tj
2.0976 0 Td
(T)Tj
0.8277 0 Td
(cell)Tj
1.5647 0 Td
(decline,)Tj
3.3052 0 Td
(it)Tj
0.7824 0 Td
(does)Tj
2.0409 0 Td
(not)Tj
1.5704 0 Td
(completely)Tj
4.5807 0 Td
(restore)Tj
-34.0608 -1.3039 Td
(immune)Tj
3.6226 0 Td
(function)Tj
3.6283 0 Td
([)Tj
0.83 0.64 0.02 0 k
(2)Tj
0 g
(].)Tj
1.6044 0 Td
(Indeed,)Tj
3.2372 0 Td
(it)Tj
0.7823 0 Td
(has)Tj
1.5421 0 Td
(recently)Tj
3.4129 0 Td
(been)Tj
2.1203 0 Td
(reported)Tj
3.6623 0 Td
(that)Tj
1.7801 0 Td
(cART)Tj
2.5569 0 Td
(is)Tj
0.8504 0 Td
(not)Tj
1.5704 0 Td
(distributed)Tj
4.5977 0 Td
(evenly)Tj
-34.9679 -1.2983 Td
(throughout)Tj
4.7791 0 Td
(the)Tj
1.4684 0 Td
(body,)Tj
2.4377 0 Td
(resulting)Tj
3.7304 0 Td
(into)Tj
1.8425 0 Td
(low-level)Tj
3.8041 0 Td
(virus)Tj
2.1997 0 Td
(replication)Tj
4.524 0 Td
(occurring)Tj
4.1273 0 Td
(in)Tj
1.0318 0 Td
(specific)Tj
3.1917 0 Td
(anatomical)Tj
-33.1367 -1.2983 Td
(niches,)Tj
2.9933 0 Td
(such)Tj
2.0636 0 Td
(as)Tj
1.0148 0 Td
(lymph)Tj
2.7836 0 Td
(nodes)Tj
2.5909 0 Td
(and)Tj
1.7291 0 Td
(gut)Tj
1.508 0 Td
([)Tj
0.83 0.64 0.02 0 k
(6)Tj
0 g
(].)Tj
1.6044 0 Td
(Alternatives)Tj
5.0287 0 Td
(to)Tj
1.0261 0 Td
(cART)Tj
2.5625 0 Td
(are)Tj
1.4457 0 Td
(therefore)Tj
3.855 0 Td
(needed.)Tj
3.3222 0 Td
(Immune)Tj
-33.5279 -1.3039 Td
(intervention)Tj
5.176 0 Td
(strategies)Tj
3.9231 0 Td
(such)Tj
2.0579 0 Td
(as)Tj
1.0148 0 Td
(therapeutic)Tj
4.7339 0 Td
(vaccination)Tj
4.8245 0 Td
(could)Tj
2.4548 0 Td
(offer)Tj
2.0976 0 Td
(an)Tj
1.2019 0 Td
(attractive)Tj
3.9231 0 Td
(alternative)Tj
4.422 0 Td
(for)Tj
-35.8296 -1.2983 Td
(cART:)Tj
2.7836 0 Td
(with)Tj
1.9955 0 Td
(fewer)Tj
2.4151 0 Td
(side)Tj
1.7972 0 Td
(effects,)Tj
2.9537 0 Td
(no)Tj
1.2756 0 Td
(need)Tj
2.1429 0 Td
(for)Tj
1.3833 0 Td
(lifelong)Tj
3.2145 0 Td
(strict)Tj
2.2394 0 Td
(therapy)Tj
3.2428 0 Td
(adherence,)Tj
4.5524 0 Td
(better)Tj
2.5398 0 Td
(availability)Tj
-32.5358 -1.2982 Td
(and)Tj
1.7291 0 Td
(cost)Tj
1.8085 0 Td
(reduction.)Tj
4.3426 0 Td
(Many)Tj
2.5512 0 Td
(therapeutic)Tj
4.7281 0 Td
(HIV)Tj
2.024 0 Td
(vaccination)Tj
4.8245 0 Td
(studies)Tj
2.9877 0 Td
(have)Tj
2.0579 0 Td
(been)Tj
2.126 0 Td
(conducted,)Tj
4.6545 0 Td
(some)Tj
-33.8341 -1.2983 Td
(with)Tj
1.9955 0 Td
(encouraging)Tj
5.2044 0 Td
(results)Tj
2.8063 0 Td
([)Tj
0.83 0.64 0.02 0 k
(7)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
(8)Tj
0 g
(])Tj
2.0749 0 Td
(as)Tj
1.0148 0 Td
(demonstrated)Tj
5.7657 0 Td
(by)Tj
1.1792 0 Td
(a)Tj
0.6519 0 Td
(reduction)Tj
4.1159 0 Td
(of)Tj
1.0148 0 Td
(plasma)Tj
3.0331 0 Td
(viral)Tj
1.9955 0 Td
(load)Tj
1.9333 0 Td
(\(lower)Tj
2.7892 0 Td
(set)Tj
-35.5745 -1.3039 Td
(point\))Tj
2.6985 0 Td
(or)Tj
1.0942 0 Td
(a)Tj
0.6576 0 Td
(prolonged)Tj
4.3313 0 Td
(time)Tj
2.0296 0 Td
(of)Tj
1.0148 0 Td
(therapy)Tj
3.2485 0 Td
(interruption)Tj
5.1647 0 Td
([)Tj
0.83 0.64 0.02 0 k
(9)Tj
0 g
(].)Tj
1.6044 0 Td
(In)Tj
1.1055 0 Td
(these)Tj
2.2564 0 Td
(therapeutic)Tj
4.7281 0 Td
(vaccination)Tj
4.8302 0 Td
(stud-)Tj
-34.7638 -1.2983 Td
(ies,)Tj
1.4966 0 Td
(a)Tj
0.652 0 Td
(range)Tj
2.4661 0 Td
(of)Tj
1.0148 0 Td
(clinical)Tj
3.0728 0 Td
(and)Tj
1.7291 0 Td
(laboratory)Tj
4.354 0 Td
(parameters)Tj
4.6714 0 Td
(was)Tj
1.7008 0 Td
(assessed)Tj
3.4696 0 Td
(to)Tj
1.0261 0 Td
(monitor)Tj
3.5376 0 Td
(vaccine)Tj
3.1975 0 Td
(safety,)Tj
2.7042 0 Td
(but)Tj
-35.0926 -1.2982 Td
(no)Tj
1.2755 0 Td
(classical)Tj
3.4129 0 Td
(correlates)Tj
4.0819 0 Td
(of)Tj
1.0148 0 Td
(vaccine)Tj
3.1918 0 Td
(efficacy)Tj
3.2258 0 Td
(could)Tj
2.4491 0 Td
(be)Tj
1.1509 0 Td
(identified)Tj
4.0591 0 Td
(to)Tj
1.0262 0 Td
(guide)Tj
2.4321 0 Td
(next)Tj
1.9559 0 Td
(generation)Tj
4.507 0 Td
(vaccine)Tj
-33.783 -1.3039 Td
(trials.)Tj
2.4207 0 Td
(Therefore,)Tj
4.3937 0 Td
(other)Tj
2.3471 0 Td
(readouts)Tj
3.6736 0 Td
(have)Tj
2.058 0 Td
(been)Tj
2.1203 0 Td
(used)Tj
2.0636 0 Td
(to)Tj
1.0205 0 Td
(assess)Tj
2.5228 0 Td
(the)Tj
1.4683 0 Td
(effect)Tj
2.3698 0 Td
(of)Tj
1.0148 0 Td
(vaccination,)Tj
5.0513 0 Td
(including)Tj
4.0421 0 Td
(a)Tj
-36.5666 -1.2983 Td
(decrease)Tj
3.6056 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4683 0 Td
(viral)Tj
1.9956 0 Td
(set)Tj
1.3039 0 Td
(point)Tj
2.3584 0 Td
(after)Tj
2.0353 0 Td
(therapy)Tj
3.2485 0 Td
([)Tj
0.83 0.64 0.02 0 k
(8)Tj
0 g
(].)Tj
-15.8342 -1.2983 Td
(In)Tj
1.1111 0 Td
(the)Tj
1.4684 0 Td
(phase)Tj
2.4831 0 Td
(I/IIa)Tj
2.0069 0 Td
(clinical)Tj
3.0728 0 Td
(trial)Tj
1.8368 0 Td
(DC-TRN,)Tj
4.9493 0 Td
(we)Tj
1.3266 0 Td
(vaccinated)Tj
4.456 0 Td
(HIV-infected)Tj
5.5729 0 Td
(individuals)Tj
4.6488 0 Td
(with)Tj
-34.1289 -1.3039 Td
(autologous)Tj
4.5977 0 Td
(dendritic)Tj
3.8778 0 Td
(cells)Tj
1.9219 0 Td
(expressing)Tj
4.422 0 Td
(HIV)Tj
2.0239 0 Td
(regulatory)Tj
4.3143 0 Td
(proteins)Tj
3.515 0 Td
([)Tj
0.83 0.64 0.02 0 k
(10)Tj
0 g
(])Tj
1.8538 0 Td
(prior)Tj
2.2507 0 Td
(to)Tj
1.0261 0 Td
(analytical)Tj
4.0082 0 Td
(cART)Tj
-33.8114 -1.2983 Td
(interruption.)Tj
5.3914 0 Td
(DC-TRN)Tj
3.9401 0 Td
(was)Tj
1.6952 0 Td
(a)Tj
0.6576 0 Td
(non-randomized,)Tj
7.2396 0 Td
(non-blinded)Tj
5.2214 0 Td
(trial)Tj
1.8368 0 Td
(evaluating)Tj
4.32 0 Td
(the)Tj
1.4684 0 Td
(safety)Tj
2.4774 0 Td
(and)Tj
-34.2479 -1.2982 Td
(immunogenicity)Tj
6.8541 0 Td
(of)Tj
1.0148 0 Td
(DC-based)Tj
4.2236 0 Td
(immunotherapy)Tj
6.7407 0 Td
(in)Tj
1.0318 0 Td
(cART-treated)Tj
5.692 0 Td
(HIV-infected)Tj
5.5728 0 Td
(patients.)Tj
3.5887 0 Td
(The)Tj
-34.7185 -1.3039 Td
(clinical)Tj
3.0727 0 Td
(protocol)Tj
3.6 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4683 0 Td
(trial)Tj
1.8368 0 Td
(has)Tj
1.5421 0 Td
(been)Tj
2.1259 0 Td
(detailed)Tj
3.3676 0 Td
(in)Tj
1.0318 0 Td
(Allard)Tj
2.7326 0 Td
(et)Tj
0.9411 0 Td
(al)Tj
0.9014 0 Td
([)Tj
0.83 0.64 0.02 0 k
(10)Tj
0 g
(].)Tj
2.0749 0 Td
(Briefly,)Tj
3.0784 0 Td
(17)Tj
1.1679 0 Td
(HIV-1)Tj
2.8516 0 Td
(subtype)Tj
3.3109 0 Td
(B)Tj
-36.1188 -1.2983 Td
(infected)Tj
3.4185 0 Td
(males,)Tj
2.7326 0 Td
(stable)Tj
2.4888 0 Td
(on)Tj
1.2756 0 Td
(cART,)Tj
2.7836 0 Td
(were)Tj
2.1203 0 Td
(vaccinated)Tj
4.456 0 Td
(both)Tj
2.0636 0 Td
(subcutaneously)Tj
6.3666 0 Td
(and)Tj
1.7291 0 Td
(intra-dermally)Tj
6.0151 0 Td
(on)Tj
-35.4498 -1.2983 Td
(four)Tj
1.9105 0 Td
(occasions)Tj
4.0535 0 Td
(with)Tj
1.9956 0 Td
(four-week)Tj
4.2973 0 Td
(intervals)Tj
3.6226 0 Td
(\()Tj
0.83 0.64 0.02 0 k
(Fig)Tj
1.8199 0 Td
(1)Tj
0 g
(,)Tj
0.9184 0 Td
(for)Tj
1.389 0 Td
(patient)Tj
3.0047 0 Td
(characteristics,)Tj
6.1341 0 Td
(please)Tj
2.6249 0 Td
(see)Tj
0.83 0.64 0.02 0 k
1.4286 0 Td
(Table)Tj
2.4378 0 Td
(1)Tj
0 g
(\).)Tj
-35.6369 -1.2982 Td
(The)Tj
1.7801 0 Td
(vaccine)Tj
3.1975 0 Td
(consisted)Tj
3.9344 0 Td
(of)Tj
1.0148 0 Td
(autologous)Tj
4.6035 0 Td
(mature)Tj
3.0954 0 Td
(DCs)Tj
1.9785 0 Td
(electroporated)Tj
5.9924 0 Td
(with)Tj
1.9956 0 Td
(sig-Tat-DC-Lamp,)Tj
7.6422 0 Td
(sig-)Tj
-35.2344 -1.304 Td
(Rev-DC-Lamp)Tj
6.1284 0 Td
(or)Tj
1.0999 0 Td
(sig-Nef-DC-Lamp)Tj
7.5174 0 Td
(mRNA)Tj
3.0841 0 Td
([)Tj
0.83 0.64 0.02 0 k
(11)Tj
0 g
(].)Tj
2.0749 0 Td
(Two)Tj
2.0239 0 Td
(weeks)Tj
2.6079 0 Td
(after)Tj
2.0353 0 Td
(the)Tj
1.4683 0 Td
(last)Tj
1.559 0 Td
(vaccination,)Tj
-29.5991 -1.2982 Td
(patients)Tj
3.3675 0 Td
(were)Tj
2.1203 0 Td
(submitted)Tj
4.2519 0 Td
(to)Tj
1.0262 0 Td
(analytical)Tj
4.0081 0 Td
(treatment)Tj
4.1329 0 Td
(interruption)Tj
5.1647 0 Td
(\(ATI\).)Tj
2.7609 0 Td
(CD4)Tj
2.0977 0 Td
(or)Tj
1.0998 0 Td
(CD8)Tj
2.092 0 Td
(T-cell)Tj
-32.122 -1.2983 Td
(responses)Tj
4.0932 0 Td
(as)Tj
1.0147 0 Td
(measured)Tj
4.1103 0 Td
(by)Tj
/F10 1 Tf
1.1792 0 Td
[()1()]TJ
1.0771 0 Td
[()-13()15()3()]TJ
/F5 1 Tf
1.8199 0 Td
(stimulation)Tj
4.7961 0 Td
(assays)Tj
2.6249 0 Td
(were)Tj
2.1203 0 Td
(used)Tj
2.0636 0 Td
(to)Tj
1.0262 0 Td
(assess)Tj
2.5171 0 Td
(the)Tj
1.474 0 Td
(vaccine)Tj
3.1918 0 Td
(responses)Tj
-33.1084 -1.3039 Td
([)Tj
0.83 0.64 0.02 0 k
(10)Tj
0 g
(].)Tj
2.0749 0 Td
(Additionally,)Tj
5.4538 0 Td
(the)Tj
1.4684 0 Td
(time)Tj
2.0296 0 Td
(off)Tj
1.3039 0 Td
(cART,)Tj
2.7836 0 Td
(which)Tj
2.6532 0 Td
(ranged)Tj
2.9877 0 Td
(from)Tj
2.2053 0 Td
(3)Tj
0.6974 0 Td
(months)Tj
3.2825 0 Td
(to)Tj
1.0261 0 Td
(7)Tj
0.6973 0 Td
(years,)Tj
2.4888 0 Td
(was)Tj
1.6951 0 Td
(used)Tj
2.0636 0 Td
(as)Tj
1.0148 0 Td
(a)Tj
-35.926 -1.2983 Td
(vaccine)Tj
3.1917 0 Td
(response)Tj
3.7361 0 Td
(variable)Tj
3.3562 0 Td
(as)Tj
1.0148 0 Td
(this)Tj
1.6724 0 Td
(approaches)Tj
4.7395 0 Td
(the)Tj
1.4683 0 Td
(`functional)Tj
4.5354 0 Td
(cure')Tj
2.1827 0 Td
(that)Tj
1.7745 0 Td
(immunotherapy)Tj
6.7407 0 Td
(aims)Tj
2.0977 0 Td
(to)Tj
ET
Q
q
1 j
1 J
0 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.2598 107.1496 23.6976 re
W* n
q
107.0929 0 0 23.6409 36 741.3165 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0 w
7.9999 0 0 7.9999 430.8094 745.7952 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(Protein)Tj
3.3307 0 Td
(profiles)Tj
3.3803 0 Td
(of)Tj
1.0347 0 Td
(HIV-DC)Tj
3.6213 0 Td
(immunother)Tj
5.1945 0 Td
(apy)Tj
ET
Q
q
1 j
1 J
0 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
0.83 0.64 0.02 0 k
81.5811 34.9228 m
237.8835 34.9228 l
h
f*
0 g
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(PLOS)Tj
2.8559 0 Td
(ONE)Tj
2.3669 0 Td
(|)Tj
0.83 0.64 0.02 0 k
0.4748 0 Td
(https://doi.or)Tj
5.4142 0 Td
(g/10.137)Tj
3.8198 0 Td
(1/journal.po)Tj
5.1236 0 Td
(ne.01922)Tj
4.089 0 Td
(78)Tj
0 g
2.0906 0 Td
(February)Tj
4.1599 0 Td
(1,)Tj
1.0417 0 Td
(2018)Tj
33.7042 0 Td
(2)Tj
0.7654 0 Td
(/)Tj
0.496 0 Td
(17)Tj
/F8 1 Tf
-0.025 Tc
-66.402 84.0904 Td
(AID)Tj
1.5874 0 Td
(project\);)Tj
3.2953 0 Td
(and)Tj
1.5874 0 Td
(by)Tj
1.1197 0 Td
(the)Tj
1.3677 0 Td
(Dutch)Tj
2.4307 0 Td
(Fund)Tj
2.0622 0 Td
(for)Tj
1.2544 0 Td
(Economic)Tj
-14.7048 -1.3748 Td
(Structure)Tj
3.6638 0 Td
(Reinforce)Tj
3.5504 0 Td
(ment,)Tj
2.3457 0 Td
(the)Tj
1.3748 0 Td
(NeuroBas)Tj
3.6284 0 Td
(ic)Tj
-14.5631 -1.3749 Td
(PharmaPhe)Tj
4.3228 0 Td
(nomics)Tj
2.9552 0 Td
(project)Tj
2.7638 0 Td
(\(ref.)Tj
1.7362 0 Td
(0908\).)Tj
2.6504 0 Td
(SB)Tj
1.2685 0 Td
(was)Tj
1.7008 0 Td
(also)Tj
-17.3977 -1.3748 Td
(supported)Tj
3.9897 0 Td
(by)Tj
1.1197 0 Td
(a)Tj
0.6378 0 Td
(grant)Tj
2.1544 0 Td
(from)Tj
2.0055 0 Td
(the)Tj
1.3748 0 Td
(Stanley)Tj
2.9268 0 Td
(Medical)Tj
-14.2087 -1.3748 Td
(Research)Tj
3.6992 0 Td
(Institute)Tj
3.2173 0 Td
(\(SMRI\).)Tj
3.182 0 Td
(JLA)Tj
1.6441 0 Td
(was)Tj
1.7008 0 Td
(supported)Tj
3.9898 0 Td
(by)Tj
-17.4332 -1.3748 Td
(the)Tj
1.3677 0 Td
(Wetenschappe)Tj
5.4851 0 Td
(lijk)Tj
1.2189 0 Td
(Fonds)Tj
2.4874 0 Td
(Willy)Tj
2.0268 0 Td
(Gepts)Tj
2.374 0 Td
(of)Tj
0.9496 0 Td
(the)Tj
1.3748 0 Td
(UZ)Tj
-17.2843 -1.3748 Td
(Brussel.)Tj
3.2102 0 Td
(The)Tj
1.5874 0 Td
(funders)Tj
3.0473 0 Td
(had)Tj
1.5874 0 Td
(no)Tj
1.1622 0 Td
(role)Tj
1.6158 0 Td
(in)Tj
0.8858 0 Td
(study)Tj
2.2678 0 Td
(design,)Tj
-15.3639 -1.3748 Td
(data)Tj
1.7929 0 Td
(collection)Tj
3.7347 0 Td
(and)Tj
1.5945 0 Td
(analysis)Tj
2.9622 0 Td
(,)Tj
0.4464 0 Td
(decision)Tj
3.2883 0 Td
(to)Tj
0.9496 0 Td
(publish,)Tj
3.1465 0 Td
(or)Tj
-17.9151 -1.3748 Td
(preparation)Tj
4.4433 0 Td
(of)Tj
0.9496 0 Td
(the)Tj
1.3677 0 Td
(manuscript.)Tj
/F7 1 Tf
-6.7606 -2.126 Td
(Competing)Tj
4.3795 0 Td
(interests)Tj
3.3307 0 Td
(:)Tj
/F8 1 Tf
0.4819 0 Td
(We)Tj
1.4457 0 Td
(also)Tj
1.7292 0 Td
(provide)Tj
2.9835 0 Td
(an)Tj
1.1126 0 Td
(updated)Tj
-15.4631 -1.3749 Td
(Conflict)Tj
3.0118 0 Td
(of)Tj
0.9496 0 Td
(Interest)Tj
3.026 0 Td
(statement:)Tj
4.1244 0 Td
(JDC)Tj
1.7575 0 Td
(and)Tj
1.5875 0 Td
(SB)Tj
1.2685 0 Td
(were)Tj
-15.7253 -1.3748 Td
(consultants)Tj
4.5 0 Td
(for)Tj
1.2614 0 Td
(Myriad-Ge)Tj
3.8835 0 Td
(netics)Tj
2.4095 0 Td
(Inc.)Tj
1.5945 0 Td
(until)Tj
1.8071 0 Td
(June)Tj
-15.456 -1.3748 Td
(2014.)Tj
2.3386 0 Td
(JT)Tj
1.1126 0 Td
(was)Tj
1.7008 0 Td
(a)Tj
0.6448 0 Td
(consultant)Tj
4.082 0 Td
(for)Tj
1.2543 0 Td
(Psynova)Tj
3.3804 0 Td
(Neurotech)Tj
-14.5135 -1.3748 Td
(Ltd.)Tj
1.6441 0 Td
(until)Tj
1.8071 0 Td
(April)Tj
1.9134 0 Td
(2016.)Tj
2.3386 0 Td
(SB)Tj
1.2685 0 Td
(is)Tj
0.8362 0 Td
(a)Tj
0.6449 0 Td
(director)Tj
3.0685 0 Td
(of)Tj
0.9496 0 Td
(Psynova)Tj
-14.4709 -1.3748 Td
(Neurotech)Tj
4.0535 0 Td
(Ltd.)Tj
1.6512 0 Td
(and)Tj
1.5874 0 Td
(Psyomics)Tj
3.8481 0 Td
(Ltd.)Tj
1.6441 0 Td
(Dr.)Tj
1.3394 0 Td
(A.D.M.E.)Tj
-14.1237 -1.3748 Td
(Osterhaus)Tj
4.0039 0 Td
(is)Tj
0.8362 0 Td
(part)Tj
1.6725 0 Td
(time)Tj
1.8425 0 Td
(chief)Tj
1.9914 0 Td
(scientif)Tj
2.6291 0 Td
(ic)Tj
0.8363 0 Td
(officer)Tj
2.5512 0 Td
(of)Tj
-16.3631 -1.3748 Td
(Viroclinics)Tj
4.0394 0 Td
(Bioscie)Tj
2.6433 0 Td
(nces)Tj
1.963 0 Td
(B.V.,)Tj
1.9417 0 Td
(Rotterdam)Tj
3.9473 0 Td
(,)Tj
0.4465 0 Td
(The)Tj
-14.9812 -1.3748 Td
(Netherland)Tj
4.0252 0 Td
(s.)Tj
0.8716 0 Td
(This)Tj
1.7788 0 Td
(does)Tj
2.0126 0 Td
(not)Tj
1.4173 0 Td
(alter)Tj
1.8213 0 Td
(our)Tj
1.474 0 Td
(adherenc)Tj
3.4087 0 Td
(e)Tj
0.6449 0 Td
(to)Tj
-17.4544 -1.3749 Td
(PLOS)Tj
2.3315 0 Td
(ONE)Tj
1.8708 0 Td
(policies)Tj
3.0119 0 Td
(on)Tj
1.1622 0 Td
(sharing)Tj
2.9835 0 Td
(data)Tj
1.7929 0 Td
(and)Tj
ET
endstream
endobj
34 0 obj
<>stream
endstream
endobj
35 0 obj
<>stream
endstream
endobj
36 0 obj
<>stream
endstream
endobj
37 0 obj
<>stream
endstream
endobj
38 0 obj
<>stream
endstream
endobj
39 0 obj
<>stream
endstream
endobj
40 0 obj
<>stream
endstream
endobj
41 0 obj
<>stream
endstream
endobj
42 0 obj
<>stream
endstream
endobj
43 0 obj
<>stream
endstream
endobj
44 0 obj
<>stream
endstream
endobj
45 0 obj
<>stream
endstream
endobj
46 0 obj
<>stream
BT
14.7402 58.5925 Td
(materials.)Tj
ET
Q
endstream
endobj
47 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 12 0 R/Annots 50 0 R/Contents 51 0 R/TrimBox[0 0 612 792]>>
endobj
49 0 obj
<>stream
x }?y*R2PJ)sEH*
Kï44
QxФ4h(e
I%TTzLY_{{~^{>{;@A @A @A @A @A @A @A @A @A @A 0<:@G ]
A @A o",_{Yg_G? @A 0 \jУE]t6mv/n+6s9^8 /C@A @r;{lcEo}gm'c6@A @g&Ϛ5?V??O
V[ @A :A`VmO)E2?>d @A -/?ڜL[Ҟ @A 8X`eDž$T>Oa_}I" @A 0}SϮZ?"- A @A`)O1@A !kA0oe:ꨖ2S~<
A @AtΔ?i_ݿoMo;?OҺE/:裝/2뮻9S&ob%\mo{Ygc?<\%osEwux]wuwF9Fկ~o~t3(|ɯ}kn&
l/rcYmtYE[-Կvٍ}_Ծ唿[XՄvS_wq?OK_r%k/ ^/8K,g z{zA2ͧk_?^/5<*D)@A 4BswM^z]:D{s]c52N^j6pC=","8ܽ]o{nv{キ쳏L>qfGH
r}_>!dvyDKgyz7o7{ޣZR;Ȥ|֣>|3]'CMwaҰZ8Ӟ4^lf}vT;jKE]EmH3&FІB÷~{鷾-N;pw/Wg?[pU.x/˝=C~^ ?/~_Wq#8y{Rla#! @A #3e7/~yL_j9E
-9zCfk_gC~a_Npb/}c͡я~8DkPUVY[wjL] wr-'[(.غC3;ӟO)'g@A @^tȔ/~TNPr%t^KPVKa&P,+PsUvrX>w2LjNaJB-Tܬ]UX) Z-:K ^n,R/-l53
/gS~^W3_%ʸlAI_"*oI)'@A @vtȔFRd+b;]ˠZ5\Ss;YGCvTUIb/|rzNg#;nh\ǒ;+`%~O^{Us$pO[n%:%1TƏ)kծ콛UIyƔg۷Bfr/-c~ ']M}l,UaᤌScvdɚWȳ3xg٥8&(O)'g@A @^tȔ9"Su%dj94Y
%믯9Ttax]YdV£K#,]AKfԪ's-Vbf[ΦnZ+vVa':tJ[w6/f8z3Goo9%|;[6SWl%*g?z81BZY Zu*־yvh:Ly(& A @A`"!SۙvY5l=E*C_,NKVW63rM(ZUVxtW1[;ڦ-3jj.J[m,.Kf4eX>|5i)i=.U>jK_d}6OU^1gqa[ Ik;s~̀m.]a#! @A #0e cU50\YcS
KrurReh3K¶0V@ԯC3ЖLee/c]ymíXYNasOoXw
7SNQR;o4ȯ{Et7um!nͧҤ-ͮ =uߖZlIF={E\5U^|F!8.5/2/k;3kSjVXn$f5Zġj*@rR91ԕ nkf%|6O%zZ~..EzֳbYKnf妈-Lp9վLof~3͇ڽ*w4b4̭i(Y8'M6i\Mf3FJ)L@A @t_,ʓ|1oԼz橒&Z9ZݷܝW2l!^-Вar'(LA @eaA @A aʃ4/)7 A @A " ^A
98L: @A 0MXopyN.]GVvj; @A !p7b+pOw<FzHׂ@A @<f͚,/vޥG?l[mSeɻWjA @A ;6l(v/t.XK^?=]A @As=۪r/# mowۃ[ @A @A @A @A @A @A @A @A @A @A @A @A @A @A @A @A _xw^~g}3o}[]vٹA %s1^[o= My8A @h?|Zprxf{s:NN}Ө/ij3O?nW,sSwFA @"_b^|-&gV֧rQ/L @w
mYYhvaTzZ4>A @1W]uo<3fkGqr @x'կ9d
A L?c?iOC{2n:@A ^wqGz{"ݩ?V
oyUV1IcMU3r @A !pV쾹QA`!`Yf*m,A @ok.[\@QR~vBΨ @3
4ywy?t6 0nj>ˢ:}$ @A 'W]uչ.UA Do\pd|@iUA ƍ[nsܸkȅA woA @<;<4y]wGA paH?vKA "O/xN&T`#/~3L{.vOӻ @A >O҃|ߘHgqл馛=>Dj˵"`{מ^xwޙ]:m"?K%\ԉ ?z뮻<\~ӣ:ޥdA @"h饗_p?O_j-r"q?*U @{FmlVxFL;wryʌs~_WD{^{cHv~yw{-bzyk^Ӌv>9y7S2 @Aя~Dr 'aڵ^;^j*aǾ_jT~l]\_|qh?ϵO
O7^cE _dJOӗYf%73;6{{d3S>^8j6)XA |#uh|+T<,:?K,袗^z8%"ӟBddFX)Ύ8g}_^x{ソ/<=X+LN1dW70V9կs1zֳ|z70t3e@A huϙg _ȴ?nggl@uK8#~/}]uUÙ}}yG$:GՄ;;.[d;輶^0 "{{0;bA @}J+*a_җW[l=ei71O]wuԧbsO>XM&s|ի^EFwk6j=ʳ:+ޑ1Y`~$M}ݿ/o_{}[2sM1AIaO|lt4n-`aJӋAbΦLA @"o~C_;aGgyzLtS)<*|O<$Gy$cTxsꍵoQI]kd*{Jds=q찶!.bJ|CSNy^g;`g馛cu]N @A >D@jcjH@WX@\W^Y >% 0%>}K.6%K;v]묳͉4㜓,IGq!{Ldo|kfBF!Agȓ^dA tGM5=mf)}oWs97O:$j_{NU-\e%h^YvxWfOP(sGɿs,=쳋uiL_}Ö^%'GM&3 %Snkx;ߙ]@A >J!\pmfU*WeQ : γ/F
L
@otw9I@aVf1eAl?aTEkQK_@c>m]''U>P'Zku`;A@7-!)@A 3#Cу,p{t=,}9}6[HEmy